Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | SORD | Q00796 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501160 | 0.68 | ALDH1A1 (0.41) | KDM4ELMNA | |
| SCHEMBL6499125 | 0.67 | PDE9A (0.34) | — | |
| SCHEMBL12929415 | 0.67 | KDM4E (0.35) | KDM4ESORDLMNAL3MBTL1RXFP1 | |
| SCHEMBL5000576 | 0.66 | HSP90AA1 (0.40) | KDM4ESORDLMNAL3MBTL1P4HTM | |
| SCHEMBL3635939 | 0.66 | SORD (0.32) | KDM4ESORDLMNAL3MBTL1MAOB | |
| SCHEMBL1477438 | 0.66 | PLD1 (0.36) | KDM4ESORDLMNAL3MBTL1MAOB | |
| Hydrochloric Acid SCHEMBL6284816 | 0.64 | SORD (0.31) | KDM4ESORDLMNAL3MBTL1 | |
| SCHEMBL2646639 | 0.64 | SORD (0.40) | KDM4ESORDLMNAL3MBTL1GPR119 | |
| SCHEMBL29118397 | 0.64 | MAOB (0.37) | KDM4ESORDLMNAL3MBTL1RXFP1 | |
| SCHEMBL27923541 | 0.63 | PLD1 (0.44) | KDM4ESORDLMNAL3MBTL1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | KDM4E 182/4885SORD 2032/4885LMNA 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.